EVUSHELD 150 mg + 150 mg solution for injection clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic use (Phase IV)
TURN-COVID Biobank: The Dutch cohort study tor the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2
This study looks at how well certain COVID-19 treatments work, such as Ronapreve, Evusheld, Xevudy, and Paxlovid. It’s also building a collection of samples to help understand these treatments and new ones in the future. The study is for adults with COVID-19.
For: SARS-CoV-2 infectionNetherlands - AuthorisedTherapeutic use (Phase IV)
Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies
This study looks at how well different COVID-19 vaccines work in people who've had COVID and were treated with special antibody medicines. It checks how their immune system responds over time and if getting a booster vaccine at 4 or 12 months makes a difference.
For: Covid-19 infectionItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment
This study is testing a new medicine, Sipavibart (also called AZD5156/AZD3152), to see if it can prevent COVID-19 in people with weaker immune systems. It compares the new medicine to an existing one called Evusheld or a dummy treatment, focusing on how safe and effective it is.
For: COVID-19Spain · France · Germany